Pasar al contenido principal

INNOVADORES COMPUESTOS NEUROGENICOS Y FOTOCONMUTABLES PARA ENFERMEDADES NEUROLOGICAS. DESARROLLO GUIADO POR UNA PLATAFORMA OMICA DE TOXICOLOGIA Y DE MECANISMOS DE ACCION

RTI2018-093955-B-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Synthesis and in vitro study of nitro- and methoxy-2-phenylbenzofurans as human Monoamine Oxidase inhibitors

  • Delogu, Giovanna Lucia
  • Kumar, Amit
  • Gatto, Gianluca
  • Bustelo Paz, Fernando
  • Saavedra, Lucía M
  • Rodríguez Franco, María Isabel
  • Laguna-Francia, Reyes
  • Viña Castelao, María Dolores
A new series of 2-phenylbenzofuran derivatives were designed and synthesized to determine relevant structural features for the MAO inhibitory activity and selectivity. Methoxy substituents were introduced in the 2-phenyl ring, whereas the benzofuran moiety was not substituted or substituted at the positions 5 or 7 with a nitro group. Substitution patterns on both the phenyl ring and the benzofuran moiety determine the affinity for MAO-A or MAO-B. The 2-(3-methoxyphenyl)-5-nitrobenzofuran 9 was the most potent MAO-B inhibitor (IC50 = 0.024 μM) identified in this series, whereas 7-nitro-2-phenylbenzofuran 7 was the most potent MAO-A inhibitor (IC50 = 0.168 μM), both acting as reversible inhibitors. The number and position of the methoxyl groups on the 2-phenyl ring, have an important influence on the inhibitory activity. Molecular docking studies confirmed the experimental results and highlighted the importance of key residues in enzyme inhibition.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

  • Codony, Sandra
  • Calvó-Tusell, Carla
  • Valverde, Elena
  • Osuna, Sílvia
  • Morisseau, Christophe
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Pizarro-Delgado, Javier
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Vázquez-Carrera, Manuel
  • Hammock, Bruce D.
  • Feixas, Ferran
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New flavonoid–N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer's disease endowed with neurogenic properties

  • Estrada, Martín
  • Herrera-Arozamena, Clara
  • Pérez, Concepción
  • Viña, Dolores
  • Morales-García, José A.
  • Pérez Castillo, Ana
  • Ramos, Eva
  • Romero Jódar, Alejandro
  • Laurini, E.
  • Pricl, Sabrina
  • Rodríguez-Franco, María Isabel
The design of multi-target directed ligands (MTDLs) is a valid approach for obtaining effective drugs for complex pathologies. MTDLs that combine neuro-repair properties and block the first steps of neurotoxic cascades could be the so long wanted remedies to treat neurodegenerative diseases (NDs). By linking two privileged scaffolds with well-known activities in ND-targets, the flavonoid and the N,N-dibenzyl(N-methyl)amine (DBMA) fragments, new CNS-permeable flavonoid–DBMA hybrids (1–13) were obtained. They were subjected to biological evaluation in a battery of targets involved in Alzheimer’s disease (AD) and other NDs, namely human cholinesterases (hAChE/hBuChE), β-secretase (hBACE-1), monoamine oxidases (hMAO-A/B), lipoxygenase-5 (hLOX-5) and sigma receptors (σ R/σ R). After a funnel-type screening, 6,7-dimethoxychromone–DBMA (6) was highlighted due to its neurogenic properties and an interesting MTD-profile in hAChE, hLOX-5, hBACE-1 and σ R. Molecular dynamic simulations showed the most relevant drug-protein interactions of hybrid 6, which could synergistically contribute to neuronal regeneration and block neurodegeneration., The authors gratefully acknowledge the following financial supports: Spanish Ministry of Science, Innovation and Universities (grants SAF2015-64948-C2-1-R and RTI2018-093955-B-C21 to MIRF; grant SAF2017-85199-P to APC), Spanish National Research Council (CSIC, grant PIE-201580E109 to MIRF), General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD-3827 – NRF24ADCM to MIRF), Consellería de Cultura, Educación e Ordenación Universitaria de Galicia, and the European Regional Development Fund (ERDF) (accreditation 2016–2019, ED431G/05 to DV). EL and SP gratefully acknowledge the support of NVIDIA Corporation with the donation of the Titan Xp GPU used for this research. and CH-A also thank their PhD fellowships from Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS, Colombia) and Spanish Ministry of Education (MEC, grant FPU16/01704), respectively. JAM-G is a fellow from the Biomedical Research Networking Centre on Neurodegenerative Diseases (CIBERNED, Spain)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Synthesis of 3-indolyltriazoles via Sonogashira coupling and azide-alkyne cycloaddition promoted by supported copper nanoparticles

  • Stabile, S.
  • Vitale, C. A.
  • Rodríguez-Franco, María Isabel
In this work we present the synthesis of a novel series of 3-indolyl-1,4-disubstituted 1,2,3-triazoles. The key steps in the synthetic route are shown in Scheme 1. A series of N-protected 3-iodoindoles were subjected to a Sonogashira cross-coupling reaction with trimethylsilylacetylene in presence of PdCl2(PPh)3 and CuI as catalysts and TEA as base, following the procedures described by Boger [1]. After deprotection of the silyl group, 1,2,3-triazoles were obtained through the azide-alkyne Huisgen 1,3-dipolar cycloaddition catalysed by copper nanoparticles (CuNPs) immobilized on activated carbon, which were prepared using the CuCl2-Li-4,4¿-Di-tert-butylbiphenyl (DTBB) reducing system previously reported by our group [2]., This work was performed in the Instituto de Química Médica (IQM-CSIC) with grants from the following agencies: Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R and RTI2018-093955-B-C21); Universidad Nacional del Sur, programa de Pasantías en Centros de Investigación destinada a Jóvenes Docentes.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Surface plasmon resonance for the discovery of new non-electrophilic inhibitors of KEAP1-NRF2 protein-protein interaction

  • Estrada-Valencia, M.
  • Herrera-Arozamena, Clara
  • Lagartera, Laura
  • Cuadrado, Antonio
  • Fernández-Ginés, Raquel
  • García-Yagüe, Ángel Juan
  • Morales-García, J. A.
  • Pérez-Castillo, Amalia
  • Rodríguez-Franco, María Isabel
In recent years the nuclear transcription factor (erythroid-derived 2)¿like 2 (Nrf2) has been identified as the key factor in the cell auto-protection mechanisms. Under no pathological conditions, Nrf2 is mainly located in the cytosol, bound to the Kelch like ECH associated protein 1 (Keap1). In contrast, under oxidative conditions, Keap1 changes its conformation and breaks the binding with Nrf2 allowing its accumulation and translocation to the nucleus where it induces the transcription of key antioxidant enzymes. Nrf2 dysregulation is involved in different pathologies such as cancer, cardiovascular diseases or neurodegenerative diseases, among others [1]. In recent years, a great amount of new molecules able to disrupt the interaction between Nrf2 and Keap1, have been studied, however most of them are electrophilic molecules and are prone to interact with several non-desired targets. In our group we are applying the surface plasmon resonance (SPR) technique for the identification of new non-electrophilic inhibitors of the Nrf2 - Keap1 protein-protein interaction (PPI). This kind of molecules could exhibit a more specific mechanism for the induction of Nrf2 activity. Thus, the ability of several molecules from our library to interact with the purified Kelch domain of Keap1 attached to a CM5 sensor chip has been evaluated in a SPR assay [2]. With this technique, a new hit with affinity for Keap1 was identified. The affinity value was comparable to that of the positive control ML-334, a well-known inhibitor of the Nrf2 - Keap1 PPI. Starting from this new hit, a larger family with improved potency have been obtained [3]. This new family of bis-heterocyclic compounds do not present any electrophilic character, are able to reach the central nervous system and exhibit other complementary activities such as radical scavenging and neurogenic properties, which make them potential candidates for the treatment of neurodegenerative diseases such as Alzheimer¿s disease., Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827, NRD24AD-CM); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R, RTI2018-093955-B-C21
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Lewis acid-catalysed oligomerization of methoxy- or ciano-indoles: synthesis of potential biologically active compounds

  • Sempere-Pérez, I.
  • Estrada-Valencia, M.
  • Rodríguez-Franco, María Isabel
Compounds containing the indole nucleus show an extensive assortment of biological and pharmacological activities, including analgesic, antiallergic, antibacterial, anti-HIV, antitumor, and antioxidant properties [1,2]. Recently, the synthesis and anticancer properties of alkaloids with dimeric indole scaffolds were reported [3]. Therefore, our interest was focused on the study of the oligomerization reactions of 4-, 6- and 7- substituted indoles with electron donor groups, i.e. methoxy group, and electron withdrawing groups, i.e. nitrile group, using a Lewis acid (bismuth chloride). From our results, we concluded that indole oligomerization is sensitive to the substituent on the heterocycle. Both the substituent position and the inductive effects of the substituents, determine which products and in which ratio they are formed. We were also able to propose possible mechanisms for the reaction that can explain the different products obtained for each substrate. ., Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R and RTI2018-093955-B-C21); Consejo Superior de Investigaciones Científicas (JAE-Intro18_EX-0264 a I.S.-P.)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

New neurogenic inducers with combined activities in key targets related to Alzheimer¿s disease

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, M.
  • Pérez, Concepción
  • Viña, D.
  • Michalska, Patrycja
  • León, Rafael
  • López, M. G.
  • Morales-García, J. A.
  • Pérez-Castillo, Amalia
  • Rodríguez-Franco, María Isabel
Alzheimer¿s Disease (AD) is a complex multifactorial illness with no effective cure, characterized by the irreversible memory loss and global cognitive impairment. Given that the marketed drugs act only at one single target, being a symptomatic treatment, exploration of new molecules acting in different pathways is required. In this sense, we have developed a large family of multitarget directed ligands (MTDL), which interacts in different targets related to neurodegeneration, such as the nuclear factor (erythroid-derived 2)-like 2 (Nrf2), lipoxygenase-5 (LOX-5), melatonin receptors (MT1, MT2, and MT3), and monoamine oxidases (MAO-A and MAO-B). The affinity or inhibition constants of these compounds in such targets are in the nanomolar and micromolar ranges. In general, these molecules have potent antioxidant properties (ORAC assay) and are able to penetrate into the central nervous system (CNS) by passive diffusion (PAMPA-BBB assay). Moreover, some of them are able to promote neurogenesis in vitro by inducing the maturation of neural stem cells into a neuronal phenotype. A structure-activity relationship has been stablished, reaching an optimized structure as possible candidate to treat AD, able to cross the blood brain barrier, reaching the CNS where it would act in three targets involved in the regulation of oxidative stress, as Nrf2 inducer, MT3 ligand and selective MAO B inhibitor. Furthermore, this MTDL is an effective neuroprotective and neurogenic agent., Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R and RTI2018-093955-B-C21). C.H.-A. thanks Spanish Ministry of Education for a FPU fellowship (grant FPU16/01704)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Optical control of muscular nicotinic channels with azocuroniums, photoswitchable azobenzenes bearing two N-methyl-N-carbocyclic quaternary ammonium groups

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, M.
  • Martí-Marí, Olaia
  • Pérez, Concepción
  • Fuente Revenga, Mario de la
  • Villalba-Galea, C. A.
  • Rodríguez-Franco, María Isabel
By linking two N-methyl-N-carbocyclic quaternary ammonium groups to an azobenzene scaffold in meta- or para-positions we generated a series of photoswitchable neuromuscular ligands for which we coined the term “azocuroniums”. These compounds switched between the (E)- and (Z)-isomers by light irradiation at 400–450 nm and 335–340 nm, respectively. Meta-azocuroniums were potent nicotinic ligands with a clear selectivity for the muscular nAChRs compared to neuronal α7 and α4β2 subtypes, showed good solubility in physiologic media, negligible cell toxicity, and would not reach the CNS. Electrophysiological studies in muscle-type nAChRs expressed in Xenopus laevis oocytes showed that (E)-isomers were more potent than (Z)-forms. All meta-azocuroniums were neuromuscular blockers, with the exception of the pyrrolidine derivative that was an agonist. These new meta-azocuroniums, which can be modulated ad libitum by light, could be employed as photoswitchable muscle relaxants with fewer side effects for surgical interventions and as tools to better understand the pharmacology of muscle-type nAChRs., The authors gratefully acknowledge the following financial supports: Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grants SAF2015-64948-C2-1-R and RTI2018-093955-B-C21 to MIRF), General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant S2017/ BMD-3827 e NRF24ADCM to MIRF) and Spanish National Research Council CSIC (grant PIE-202080E118). CH-A also thanks her PhD fellowships from Spanish Ministry of Education (MEC, PhD grant FPU16/01704 and mobility grant FPUEST17/00233).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, M.
  • Pérez, Concepción
  • Lagartera, Laura
  • Morales-García, José A.
  • Pérez-Castillo, Ana
  • Franco-Gonzalez, Juan Felipe
  • Michalska, Patrycja
  • Duarte, Pablo
  • León, Rafael
  • López, Manuela G.
  • Mills, Alberto
  • Gago, Federico
  • García-Yagüe, Ángel Juan
  • Fernández-Ginés, Raquel
  • Cuadrado, Antonio
  • Rodríguez-Franco, María Isabel
New multi-target indole and naphthalene derivatives containing the oxadiazolone scaffold as a bioisostere of the melatonin acetamido group have been developed. The novel compounds were characterized at melatonin receptors MTR and MTR, quinone reductase 2 (QR2), lipoxygenase-5 (LOX-5), and monoamine oxidases (MAO-A and MAO-B), and also as radical scavengers. We found that selectivity within the oxadiazolone series can be modulated by modifying the side chain functionality and co-planarity with the indole or naphthalene ring. In phenotypic assays, several oxadiazolone-based derivatives induced signalling mediated by the transcription factor NRF2 and promoted the maturation of neural stem-cells into a neuronal phenotype. Activation of NRF2 could be due to the binding of indole derivatives to KEAP1, as deduced from surface plasmon resonance (SPR) experiments. Molecular modelling studies using the crystal structures of QR2 and the KEAP1 Kelch-domain, as well as the recently described X-ray free-electron laser (XFEL) structures of chimeric MTR and MTR, provided a rationale for the experimental data and afforded valuable insights for future drug design endeavours., The authors gratefully acknowledge the following financial supports: Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grants RTI2018-093955-B-C21 and SAF2015-64948-C2-1-R to M.I.R.-F.; RTI2018-095793-B-I00 to M.G.L., SAF2015-64629-C2-2-R to F.G.), General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD-3827 e NRF24ADCM), Health Institute Carlos III (Miguel Servet II ProgramCP16/00014 and grant PI17/01700 to R.L.). CH-A and P.M. thank their PhD fellowships from Spanish Ministry of Education (MEC, PhD grant FPU16/01704 and mobility grant FPUEST17/00233 to CH-A and FPU13/03737 to P.M.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders

  • Espadinha, Margarida
  • Viejo, L.
  • Lopes, Ricardo M. R. M.
  • Herrera-Arozamena, Clara
  • Molins, Elies
  • dos Santos, D. J. V. A.
  • Gonçalves, Lídia M.
  • Rodríguez-Franco, María Isabel
  • Ríos, C. d. l.
  • Santos, María M. M.
N-Methyl-D-aspartate receptors (NMDARs) are crucial for the normal function of the central nervous system (CNS), and fundamental in memory and learning-related processes. The overactivation of these receptors is associated with numerous neurodegenerative and psychiatric disorders. Therefore, NMDAR is considered a relevant therapeutic target for many CNS disorders. Herein, we report the synthesis and pharmacological evaluation of a new scaffold with antagonistic activity for NMDAR. Specifically, a chemical library of eighteen 1-aminoindan-2-ol tetracyclic lactams was synthesized and screened as NMDAR antagonists. The compounds were obtained by chiral pool synthesis using enantiomerically pure 1-aminoindan-2-ols as chiral inductors, and their stereochemistry was proven by X-ray crystallographic analysis of two target compounds. Most compounds reveal NMDAR antagonism, and eleven compounds display IC values in a Ca entry-sensitive fluo-4 assay in the same order of magnitude of memantine, a clinically approved NMDAR antagonist. Docking studies suggest that the novel compounds can act as NMDAR channel blockers since there is a compatible conformation with MK-801 co-crystallized with NMDAR channel. In addition, we show that the tetracyclic 1-aminoindan-2-ol derivatives are brain permeable and non-toxic, and we identify promising hits for further optimization as modulators of the NMDAR function., This work was supported by FCT (Fundaç~ao para a Ci^encia e a Tecnologia, I.P.) through iMed.ULisboa (UID/DTP/04138/2019), Principal Researcher grant CEECIND/01772/2017 (M. M. M. Santos), and PhD fellowships SFRH/BD/117931/2016 (M. Espadinha) and SFRH/BD/121664/2016 (R. Lopes). Financial support from FCT and Portugal 2020 to the Portuguese Mass Spectrometry Network (Rede Nacional de Espectrometria de Massa e RNEM; LISBOA-01-0145- FEDER-402-022125) is also acknowledged. M.I.R.-F. thanks funding from the Spanish Ministry of Science, Innovation and Universities (grant RTI2018-093955-B-C21) and the technical assistance of Ms. Cristina Tortosa (European contract for young professionals). C.d.l.R. thanks funding from Instituto de Salud Carlos III, Madrid, Spain (grant PI16/01041 and PhD fellowship FI17/00079 for L. Viejo).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

  • Codony, Sandra
  • Pujol, Eugènia
  • Pizarro, J.
  • Feixas, Ferran
  • Valverde,E.
  • Loza, María Isabel
  • Brea, José Manuel
  • Saez, Elena
  • Oyarzabal, Julen
  • Pineda-Lucena, Antonio
  • Pérez, Belén
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Leiva, Rosana
  • Osuna, Sílvia
  • Morissea, Christophe
  • Hammock, Bruce D.
  • Vázquez-Carrera, Manuel
  • Vázquez, Santiago
In vivo pharmacological inhibition of soluble epoxide hydrolase (sEH) reduces inflammatory diseases, including acute pancreatitis (AP). Adamantyl ureas are very potent sEH inhibitors, but the lipophilicity and metabolism of the adamantane group compromise their overall usefulness. Herein, we report that the replacement of a methylene unit of the adamantane group by an oxygen atom increases the solubility, permeability, and stability of three series of urea-based sEH inhibitors. Most of these oxa-analogues are nanomolar inhibitors of both the human and murine sEH. Molecular dynamics simulations rationalize the molecular basis for their activity and suggest that the presence of the oxygen atom on the adamantane scaffold results in active site rearrangements to establish a weak hydrogen bond. The 2-oxaadamantane 22, which has a good solubility, microsomal stability, and selectivity for sEH, was selected for further in vitro and in vivo studies in models of cerulein-induced AP. Both in prophylactic and treatment studies, 22 diminished the overexpression of inflammatory and endoplasmic reticulum stress markers induced by cerulein and reduced the pancreatic damage., This work was funded by the Spanish Ministerio de Economía Industria y Competitividad (grants SAF2017-82771-R to S.V., SAF2015-64146-R, andMICIU/ICTI2017-2020/Referencito M.V.-C., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the CaixaImpulse 2015 Programme, the Spain EIT Health (Proof of concept 2016), the European Regional Development Fund (ERDF),the Xunta de Galicia (GRC2014/011 and ED431C2018-21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707), the Fundacion Fuentes Dutor ́ , the European Research Council (ERC-2015- StG-679001- NetMoDEzyme to S.O.), and the European Community (MSCA-IF-2014-EF-661160-MetAccembly to F.F.). S.C. and E.P. acknowledge PhD fellowships from the Universitat de Barcelona (APIF grants). E.V. and R.L. thank the Institute of Biomedicine of the University of Barcelona (IBUB) and the Spanish Ministerio de Educacion, Cultura y Deporte ́ (FPU grant), respectively, for PhD grants. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIHNIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank Daniel Closa (IIBB−CSIC, Barcelona, Spain) for advice regarding the histological analyses.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and in vitro study of nitro- and methoxy-2-phenylbenzofurans as human monoamine oxidase inhibitors

  • Delogu, G. L.
  • Kumar, A.
  • Gatto, G.
  • Bustelo, F.
  • Saavedra, Lucía M.
  • Rodríguez-Franco, María Isabel
  • Laguna, Reyes
  • Viña, Dolores
A new series of 2-phenylbenzofuran derivatives were designed and synthesized to determine relevant structural features for the MAO inhibitory activity and selectivity. Methoxy substituents were introduced in the 2-phenyl ring, whereas the benzofuran moiety was not substituted or substituted at the positions 5 or 7 with a nitro group. Substitution patterns on both the phenyl ring and the benzofuran moiety determine the affinity for MAO-A or MAO-B. The 2-(3-methoxyphenyl)-5-nitrobenzofuran 9 was the most potent MAO-B inhibitor (IC = 0.024 µM) identified in this series, whereas 7-nitro-2-phenylbenzofuran 7 was the most potent MAO-A inhibitor (IC = 0.168 µM), both acting as reversible inhibitors. The number and position of the methoxyl groups on the 2-phenyl ring, have an important influence on the inhibitory activity. Molecular docking studies confirmed the experimental results and highlighted the importance of key residues in enzyme inhibition., The financial support (ED431G 2019/02) from the Xunta de Galicia (Centro singular de investigación de Galicia accreditation 2019-2022) and the European Union (European Regional Development Fund -ERDF), is gratefully acknowledged. The present work was partially supported by FIR (Fondo Integrativo per la Ricerca – annualit`a 2018) University of Cagliari. G. L. Delogu is grateful to R. Mascia (University of Cagliari) for his technical assistance. M.I.R.-F. thanks the financial support from Spanish Ministry of Science, Innovation and Universities (grant RTI2018-093955-B-C21) and General Council for Research and Innovation of the Community of Madrid / European Structural Funds (grant B2017/BMD-3827 - NRF24ADCM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, M.
  • López-Caballero, Patricia
  • Pérez, Concepción
  • Morales-García, José A.
  • Pérez-Castillo, Ana
  • Sastre, Eric del
  • Fernández-Mendívil, Cristina
  • Duarte, Pablo
  • Michalska, Patrycja
  • Lombardía, José
  • Senar, Sergio
  • León, Rafael
  • López, Manuela G.
  • Rodríguez-Franco, María Isabel
By replacing a phenolic ring of (E)-resveratrol with an 1,3,4-oxadiazol-2(3H)-one heterocycle, new resveratrol-based multi- target-directed ligands (MTDLs) were obtained. They were evaluated in several assays related to oxidative stress and inflammation (monoamine oxidases, nuclear erythroid 2-related factor, quinone reductase-2, and oxygen radical trapping) and then in experiments of increasing complexity (neurogenic properties and neuroprotection vs okadaic acid). 5-[(E)-2-(4-Methoxyphenyl)ethenyl]-3-(prop-2-yn-1- yl)-1,3,4-oxadiazol-2(3H)-one (4e) showed a well-balanced MTDL profile: cellular activation of the NRF2-ARE pathway (CD = 9.83 μM), selective inhibition of both hMAO-B and QR2 (IC50s = 8.05 and 0.57 μM), and the best ability to promote hippocampal neurogenesis. It showed a good drug-like profile (positive in vitro central nervous system permeability, good physiological solubility, no glutathione conjugation, and lack of PAINS or Lipinski alerts) and exerted neuroprotective and antioxidant actions in both acute and chronic Alzheimer models using hippocampal tissues. Thus, 4e is an interesting MTDL that could stimulate defensive and regenerative pathways and block early events in neurodegenerative cascades., The authors gratefully acknowledge the following financial supports: the Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; European Regional Development Funds (grants RTI2018-093955-B-C21, SAF2015-64948-C2-1-R, and PID2021-122650OB-I00 to M.I.R.-F.; RTI2018-095793-B-I00 to M.G.L.); Spanish Na- tional Research Council (CSIC grants, PIE-202080E118 to M.I.R.-F. and PIE-202080I026 to R.L.); Health Institute Carlos III (grant PI17/01700 to R.L.); and General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD-3827- NRF24ADCM). They thank the Ministry of Education of Spain for the following fellowships: FPU16/01704 and mobility grant FPUEST17/00233 (to C.H.-A.), FPU15/ 03269 (to C.F.-M.), FPU18/00630 (to E.d.S.), and FPU13/ 03737 (to P.M.). R.L. and M.G.L. also thank “Fundación Teófilo Hernando” for its continued support. The Spanish Medicinal Chemistry Society (SEQT) awarded the “Lilly Prize for Young Researchers” to this work, presented by C.H.-A. at the XIX SEQT Awards., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis, in vitro profiling and in vivo evaluation of benzohomoadamantane-based ureas for visceral pain: a new indication for soluble epoxide hydrolase inhibitors

  • Codony, Sandra
  • Entrena, José M.
  • Calvó-Tusell, Carla
  • Osuna, Sílvia
  • Jora, Beatrice
  • González-Cano, Rafael
  • Corpas, Rubén
  • Morisseau, Christophe
  • Pérez, Belén
  • Barniol-Xicota, Marta
  • Griñán-Ferré, Christian
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Martínez, Antón L.
  • Loza, María Isabel
  • Pallàs, Mercè
  • Verhelst, Steven H. L.
  • Sanfeliu, Coral
  • Feixas, Ferran
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spanish MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (Grant PID2020-118127RB-I00 to S.V. and Grant PID2019-106285RB to M.P. and C.S.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-NetMoDEzyme to S.O.), and the European Community (MSCA-IF-2014-EF661160-MetAccembly to F.F.). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant) and the Spanish Society of Medicinal Chemistry (SEQT) and Lilly for an “Award for Novel Researchers in the Discovery and Development of New Drugs”. M.B.X. acknowledges FWO for a post-doctoral fellowship (no. 12Y0720N). S.H.L.V. acknowledges the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin, and the Bundesministerium für Bildung und Forschung. F.F. acknowledges Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

  • Codony, Sandra
  • Calvó-Tusell, Carla
  • Valverde, Elena
  • Osuna, Sílvia
  • Morisseau, Christophe
  • Loza, M. Isabel
  • Brea, José
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Pizarro-Delgado, Javier
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Vázquez-Carrera, Manuel
  • Hammock, Bruce D.
  • Feixas, Ferran
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093999-B-100 to M. V.-C., RTI2018-093955-B-C21 to M.I.R.-F., SAF2016-77703-C2 to M.P. and C.S., PGC2018- 102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spain EIT Health (Proof of concept 2016), the European Regional Development Fund (ERDF), the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-Net- MoDEzyme to S.O.), and the European Community (MSCA-IF- 2014-EF-661160-MetAccembly to F.F.). S.C. and E.V. acknowledge the PhD fellowships from the Universitat de Barcelona (APIF grant) and the Institute of Biomedicine of the University of Barcelona (IBUB), respectively. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain, A New Indication for Soluble Epoxide Hydrolase Inhibitors

  • Codony, Sandra|||0000-0003-0539-673X
  • Entrena, José M.|||0000-0002-4319-746X
  • Calvó-Tusell, Carla|||0000-0003-2681-8460
  • Jora, Beatrice
  • González-Cano, Rafael|||0000-0002-9657-4521
  • Osuna, Sílvia|||0000-0003-3657-6469
  • Corpas, Rubén|||0000-0002-7051-1493
  • Morisseau, Christophe
  • Pérez, Belén|||0000-0001-5801-1704
  • Barniol-Xicota, Marta|||0000-0001-7957-2199
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel|||0000-0002-6500-792X
  • Martínez, Antón L.|||0000-0002-1595-3459
  • Loza, María Isabel|||0000-0003-4730-0863
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Verhelst, Steven H. L.|||0000-0002-7400-1319
  • Sanfeliu i Pujol, Coral|||0000-0002-9004-1206
  • Feixas, Ferran|||0000-0001-5147-0000
  • Hammock, Bruce D.|||0000-0003-1408-8317
  • Brea, José|||0000-0002-5523-1979
  • Cobos, Enrique J.
  • Vázquez, Santiago|||0000-0002-9296-6026
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

  • Herrera Arozamena, Clara
  • Estrada Valencia, Martín
  • Pérez, Concepción
  • Lagartera Ortiz, Laura
  • Morales García, Jose Ángel
  • Pérez Castillo, Ana
  • Franco Gonzalez, Juan Felipe
  • Michalska, Patrycja
  • Duarte Flórez, Pablo
  • León Martínez, Rafael
  • García López, Manuela
  • Mills Fernández, Alberto|||0000-0003-4819-1638
  • Gago Badenas, Federico|||0000-0002-3071-4878
  • García Yagüe, Ángel Juan
  • Fernández Ginés, Raquel
  • Cuadrado Pastor, Antonio
  • Rodríguez Franco, María Isabel
24 p., New multi-target indole and naphthalene derivatives containing the oxadiazolone scaffold as a bioisostere of the melatonin acetamido group have been developed. The novel compounds were characterized at melatonin receptors MT1R and MT2R, quinone reductase 2 (QR2), lipoxygenase-5 (LOX-5), and monoamine oxidases (MAO-A and MAO-B), and also as radical scavengers. We found that selectivity within the oxadiazolone series can be modulated by modifying the side chain functionality and co-planarity with the indole or naphthalene ring. In phenotypic assays, several oxadiazolone-based derivatives induced signalling mediated by the transcription factor NRF2 and promoted the maturation of neural stem-cells into a neuronal phenotype. Activation of NRF2 could be due to the binding of indole derivatives to KEAP1, as deduced from surface plasmon resonance (SPR) experiments. Molecular modelling studies using the crystal structures of QR2 and the KEAP1 Kelch-domain, as well as the recently described X-ray free-electron laser (XFEL) structures of chimeric MT1R and MT2R, provided a rationale for the experimental data and afforded valuable insights for future drug design endeavours., Ministerio de Ciencia, Innovación y Universidades, Agencia Española de Investigación, Fondo Europeo de Desarrollo Regional (FEDER), Comunidad de Madrid, Instituto de Salud Carlos III, Ministerio de Educación y Ciencia, Ministerio de Economía y Competitividad